CDK Inhibition May Overcome Mechanisms of Olaparib Resistance in Prostate Cancer
September 15th 2021
By studying olaparib-sensitive and -resistant cell lines, researchers were able to gather insights regarding PARP inhibitor treatment and resistance mechanisms, including the use of CDK inhibition as a potential means of overcoming PARP inhibitor resistance in prostate cancer.